Tislelizumab and disitamab as pre-surgery treatment for HER2 UTUC
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether giving tislelizumab plus disitamab vedotin before surgery (neoadjuvant therapy) can improve outcomes for people with HER2-positive, high-risk upper tract urothelial cancer. It also looks at the treatment’s safety and helps doctors learn if certain tumor features predict response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed upper tract urothelial cancer that is HER2-positive (IHC 1+ or higher) and is high-risk by standard guidelines
- Your cancer must be localized based on scans (CT/MRI/PET-CT) and you plan surgery such as kidney-ureter-removal (RNU), distal ureter removal (DU), or ureteroscopic ablation (UA)
- You are age 18 or older, and your expected survival is more than 12 weeks
- Your overall health score (ECOG) is 0 to 2, meaning you’re not severely limited in daily activities
- You can provide required samples (blood, urine, and tumor/tissue) for multiple lab tests (like MRD and tumor markers)
- Your blood, liver, and kidney tests are strong enough for treatment (including kidney function with GFR at least 15 ml/min)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an antibody-drug conjugate (Disitamab Vedotin) plus radiation therapy after surgery to prevent upper tract urothelial cancer from coming back. It is for patients with HER2-positive tumors and high-risk features who cannot receive cisplatin chemo.
This trial tests a combination of a targeted drug (disitamab vedotin), an immunotherapy (toripalimab), and radiation before surgery for people with high-risk upper tract urothelial cancer (UTUC). The goal is to see if this approach improves outcomes before and after surgery.
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
This trial tests a targeted drug called disitamab vedotin combined with radiation after surgery for a rare type of bladder cancer in the upper urinary tract. It may be an option for people who cannot take standard chemotherapy because of kidney problems, hearing loss, or other health issues.
This trial tests a combination of immunotherapy (tislelizumab) and chemotherapy (nab-paclitaxel) given before surgery for ureteral cancer. The goal is to see if the treatment shrinks the tumor and makes the surgery more effective.
This trial tests two drugs (toripalimab and 9MW2821) given before surgery for patients with upper tract urothelial cancer that hasn't spread. The goal is to see if this combination can shrink the tumor and improve outcomes.
Hear when a new Neoadjuvant Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.